The Supplement Industry Has Trained You to Ask the Wrong Question, and Until You Ask the Right One You Will Keep Spending Money on Products That Cannot Do What They Claim
The supplement aisle has two kinds of products. A small number that have genuine human clinical trial evidence at doses that produce measurable outcomes in people like you. And everything else. The industry has spent decades ensuring you cannot tell the difference. Here is the framework that separates them, and where the MYOCODE ingredients sit when you apply it honestly.
What I have found is that the supplement industry's greatest achievement is not any particular product. It is training an entire population to ask the wrong question. The question is always some version of: does this supplement work? And the answer is almost always some variation of: research suggests it may support. Which sounds like a yes but is not actually an answer to anything.
The right question is not whether a supplement works in general. It is whether this specific compound, in this specific form, at this specific dose, has produced measurable outcomes in human clinical trials with adults who resemble the population being sold to. That question has a much shorter list of satisfying answers. And it is the question that guided every formulation decision in the MYOCODE system.
I am going to share the framework I used. Not to sell you on what I built, though I believe deeply in it. To give you a tool that makes you a better consumer of any supplement claim you encounter, including mine. Because the best thing I can do for the credibility of this brand is to teach you how to evaluate it honestly rather than ask you to take my word for it.
The Wrong Question and Why It Persists
The supplement industry is built on a regulatory framework that is, to put it charitably, not designed to protect you. In the United States, dietary supplements do not require clinical trial evidence to reach the market. They do not require proof of efficacy. They require only that they not be actively harmful and that any health claims stop short of claiming to treat or cure a disease. Everything else, the implications, the suggestions, the carefully worded associations, is fair game.
This creates a market in which the incentive is to find the cheapest, most marketable ingredient, commission or cite a study that shows any positive signal at any dose in any population, and build a product story around that signal. The fact that the signal came from a cell culture study, or a rat study, or a human study at ten times the dose in the product, or in a population with a specific deficiency the average customer does not have, is nowhere on the label.
The consumer asks: does this work? The marketer says: research supports. Both go home believing the transaction was honest. But the question was wrong, the answer was technically true and functionally meaningless, and the money spent produced nothing the biology required.
Does This Supplement Work?
This question has no useful answer. Almost every ingredient has some study supporting some effect somewhere. The industry is built around answering this question with technically accurate but practically meaningless responses that get products sold without producing outcomes.
Does This Compound, at This Dose, in This Form, Have Human Trial Evidence in My Population?
This question has a short list of satisfying answers. It eliminates cell culture studies, animal studies, underdosed trials, and studies in populations with conditions not shared by the buyer. Apply it and the supplement aisle looks very different.
When I started formulating MYO Daily, I made a rule for myself. Nothing goes in the formula that does not have human clinical trial evidence at the dose it appears in the product, in a population that resembles the adults this product is designed for. Not cell culture data. Not animal data with extrapolated human equivalents. Not a study in adults with a specific clinical deficiency that healthy midlife adults do not share. Human trials, clinical doses, relevant populations.
That rule eliminated the majority of ingredients I considered. Some genuinely interesting compounds with compelling mechanism data and zero human trial evidence at useful doses. Some ingredients with strong human trial data at doses ten times what any commercially viable product could deliver. And some ingredients that passed every test but were already in the formula in a more effective form.
What remained after applying that filter is what is in the bottle. Every active ingredient in MYO Daily appears at its full clinical dose, printed on the label. No proprietary blends. No undisclosed quantities. No hiding behind a blend that could contain any amount of anything.
The Evidence Hierarchy You Were Never Taught
Not all research is equal. The supplement industry treats all of it as if it were, because the regulatory framework allows that treatment and the business model depends on it. Here is the actual hierarchy, from least to most meaningful for making a purchasing decision.
Compounds applied directly to isolated cells in a dish produce effects that frequently do not translate to the same compound taken orally by a human being. The bioavailability is different, the metabolic pathway is different, and the concentration achievable in human tissue at a realistic dose is often orders of magnitude lower than what produced the effect in vitro. Cell culture data establishes mechanism plausibility. It is not evidence of clinical benefit.
Animal studies are more informative than cell culture data but face a fundamental translation problem. Mice are not small humans. Their metabolic rates, lifespans, and physiological responses to compounds differ in ways that make extrapolation unreliable. Many compounds that extend mouse lifespan dramatically have no meaningful effect in humans at comparable doses. Animal data is hypothesis-generating. It is not the same as human evidence.
Studies tracking what people eat or take and correlating it with health outcomes establish association, not causation. People who take more of a supplement often have other health behaviors that differ from non-users. The correlation may reflect those behaviors rather than the supplement itself. Observational evidence is useful for hypothesis generation and for identifying compounds worth studying in controlled trials. It is not the same as evidence that the compound produces the observed benefit.
A randomized controlled trial assigns participants to a supplement or placebo, controls for confounding variables, and measures specific outcomes. When this is done at the dose present in a commercial product, in a population resembling the target customer, and replicated across multiple independent research groups, it constitutes meaningful evidence that the compound produces the claimed benefit in humans. This is the standard that separates the short list of supplements with genuine evidence from everything else in the category.
A meta-analysis pools data across multiple independent randomized controlled trials to assess the consistency and magnitude of an effect across studies. When a compound shows consistent positive signals across a well-conducted meta-analysis of multiple RCTs, it has the strongest available evidence base for clinical benefit. The MYOCODE core ingredients, creatine and HMB specifically, sit at this level of the evidence hierarchy.
The Three Ways Products Fake the Evidence
Even when a product cites real human trial evidence, there are three reliable methods the industry uses to make weak evidence look strong. Learning to recognize them changes how you read every supplement claim you will ever encounter.
The wrong population problem. A study shows that compound X significantly improves outcome Y in adults with clinical deficiency Z. The product markets to generally healthy adults who do not have deficiency Z. The study is real. The effect in the marketed population may be zero. Population matters as much as dose, and it is almost never specified in the marketing.
The wrong dose problem. A study shows meaningful benefit at 3 grams per day. The product contains 300 milligrams, one tenth the effective dose, buried in a proprietary blend so the actual quantity is invisible. The citation is real. The dose is theatrical. This is the proprietary blend problem, and it is why dose transparency on a label is not a detail. It is the single most important piece of information available.
The wrong study type problem. The marketing says "clinically studied." The study is a single, small, uncontrolled pilot with no placebo group, funded by the company selling the product, showing a trend that did not reach statistical significance. Technically clinically studied. Practically meaningless. The citation exists. The evidence standard it represents does not.
First, look for a proprietary blend. If any combination of ingredients is listed under a single name with a total weight but no individual amounts, the doses are hidden and the product cannot be evaluated. Walk away or accept that you are buying a story rather than a dose.
Second, check the dose of the primary active ingredient against the clinical trial dose for that ingredient. If the label dose is less than half the dose used in the relevant human trials, the product is unlikely to produce the studied effect regardless of what the marketing claims.
Third, check whether the human trials cited used the population the product is marketed to. A study in elite athletes is not evidence of benefit in sedentary midlife adults. A study in adults with a clinical deficiency is not evidence of benefit in generally healthy people.
The MYOCODE Ingredients Through the Right Lens
Here is what happens when you apply the right question to the ingredients in the MYOCODE system. Not a curated selection of the most favorable studies. Every primary active, evaluated against the framework above.
Over 500 randomized controlled trials. Multiple independent meta-analyses confirming benefit for muscle mass, strength, cognitive function, and metabolic health. The most studied supplement in sports science history. MYO Daily delivers 5g, the dose used in the overwhelming majority of published trials. Evidence level: the strongest available in the supplement category.
Multiple randomized controlled trials and a systematic review confirming muscle preservation benefit in adults undergoing resistance training, caloric restriction, and periods of inactivity. MYO Daily delivers 3g, the dose used in the clinical trials showing significant lean mass preservation. The trademarked myHMB form is the specific form used in the majority of published human research. Evidence level: strong, with multiple independent replications.
Human randomized controlled trials confirming that NR supplementation at 250 to 1000mg daily raises NAD+ concentrations in blood and muscle tissue in healthy middle-aged and older adults. MYO Daily delivers 350mg, within the range used in published human trials. The caveat worth naming: NAD+ elevation is well-established; whether specific longevity outcomes translate fully to humans remains an active research area. The mechanism is sound and the human bioavailability evidence is solid. Evidence level: strong for the specific claim of NAD+ elevation; emerging for downstream longevity outcomes.
P-5-P, L-5-MTHF, and methylcobalamin are the bioactive forms of B6, B9, and B12, included specifically because they do not require conversion steps that decline in efficiency with age and are impaired in adults with MTHFR and MTRR variants. Human research on active versus standard B-vitamin forms in bioavailability and methylation cycle support is well-established. Evidence level: strong for form superiority in the target population, with personal clinical rationale based on Christine's own genetic variants.
Human randomized controlled trials confirming that leucine concentration per meal, not total daily protein, is the primary determinant of muscle protein synthesis response, and that older adults require a higher leucine dose per meal than younger adults to cross the anabolic threshold. The pea and rice isolate blend with added L-leucine addresses both the amino acid profile requirement and the leucine threshold specifically. Evidence level: strong for the leucine threshold mechanism; the specific plant protein blend with added leucine follows directly from the established science.
Human randomized controlled trials confirming that chromium picolinate supplementation supports insulin receptor sensitivity and improves glucose metabolism in adults with impaired glucose regulation, relevant to the insulin sensitivity decline common in midlife adults. 200mcg is within the range of the published trial doses. Evidence level: moderate to strong, with the strongest evidence in adults with existing glucose dysregulation and meaningful supportive evidence in the broader midlife population.
Every active ingredient in the MYOCODE system is listed at its full dose on the label. No proprietary blends. No hidden quantities. The transparency is not a marketing choice. It is the minimum standard a formula with genuine clinical evidence should be willing to meet.
What Honest Supplement Claims Look Like
Honest supplement claims do not oversell. They do not imply certainty where the research shows probability. They do not extrapolate animal data to human outcomes. And they name what is known and what is still being established, because an honest brand can afford to do that without losing the case for its products.
Here is what the MYOCODE system claims, stated at the level the evidence actually supports. Creatine at 5g daily has robust, replicated, multi-meta-analysis evidence for muscle and cognitive benefit in adults. myHMB at 3g daily has replicated human trial evidence for muscle preservation in the specific conditions most relevant to the midlife adult. NR at 350mg has strong human evidence for NAD+ elevation and emerging evidence for downstream longevity outcomes. The active B-vitamins address a documented bioavailability gap that is relevant to a large proportion of the target population. The leucine-dosed protein addresses a documented anabolic resistance mechanism with strong human trial support.
None of those claims require a single cell culture study or a rat lifespan extension. They stand on human clinical trial evidence at clinical doses in relevant populations. That is the standard. That is what separates this from the category it competes in.
I want to be honest about something. Building a formula to this standard is more expensive than building one that does not. Clinical doses of creatine, myHMB, and NR cost more than token amounts of the same ingredients hiding in a proprietary blend. Active B-vitamin forms cost more than synthetic ones. And being willing to print every dose on the label means there is nowhere to hide if the doses are not meaningful.
I made those choices deliberately, not because they produce the best margins but because the person buying this product deserves to know exactly what they are getting and exactly why it is there. The framework I described in this article is the framework I used to build the formula. Apply it to any supplement you are considering, including this one. If it holds up, the product earns your trust. If it does not, you have saved yourself money that could go toward something that does.
The right question is the most powerful consumer protection tool available. Use it every single time.
The Bottom Line
The supplement industry will keep selling you research suggests as long as you keep accepting it as an answer. The moment you change the question, from does this work to does this specific compound at this dose have human trial evidence in my population, the answer gets a lot more specific and a lot more honest.
There is a short list of supplements that pass that test. They are not necessarily the most marketed ones. They are not always the most expensive or the most creatively branded. They are the ones where someone cared enough about the evidence to formulate at clinical doses and print those doses on the label, and where the human research at those doses in relevant populations supports what is being claimed.
That is the standard. Hold every product you consider to it, and you will spend less, get more, and stop wondering why the supplements you have been taking are not doing what the label promised.
Every active at its clinical dose. Printed on the label.
Creatine 5g. myHMB® 3g. NR 350mg. Active B-vitamins. Leucine-dosed plant protein. No proprietary blends. No hidden quantities. The framework applied to the formula, transparently.
Shop the System Shop MYO Daily- Kreider RB, et al. "International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine." Journal of the International Society of Sports Nutrition. 2017;14:18.
- Wilson JM, et al. "International Society of Sports Nutrition position stand: beta-hydroxy-beta-methylbutyrate (HMB)." Journal of the International Society of Sports Nutrition. 2014;11:38.
- Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. 2018;9(1):1286.
- Katsanos CS, et al. "A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly." American Journal of Clinical Nutrition. 2006;83(2):384–389.
- Anderson RA, et al. "Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables." Metabolism. 1983;32(9):894–899.
- Friso S, et al. "A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status." PNAS. 2002;99(8):5606–5611.
- Avgerinos KI, et al. "Effects of creatine supplementation on cognitive function of healthy individuals." Experimental Gerontology. 2018;108:166–173.
- Chilibeck PD, et al. "Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis." Open Access Journal of Sports Medicine. 2017;8:213–226.